Trial Outcomes & Findings for Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care (NCT NCT01716169)

NCT ID: NCT01716169

Last Updated: 2016-05-05

Results Overview

Change was assessed in terms of wound surface area, as measured using the ARANZ camera. Week 8 surface area measurement was compared to baseline surface area measurement and percentage in size change was calculated.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

10 participants

Primary outcome timeframe

Baseline and Week 8

Results posted on

2016-05-05

Participant Flow

Recruitment from EB Clinic patients, organization website

Participant milestones

Participant milestones
Measure
Helicoll - Chronic Wound
Helicoll will be applied to one chronic wound (approximately 6 months or more duration) Helicoll: Helicoll Collagen I Wound Dressing
Overall Study
STARTED
10
Overall Study
Standard of Care Dressings Used
7
Overall Study
COMPLETED
6
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Helicoll - Chronic Wound
Helicoll will be applied to one chronic wound (approximately 6 months or more duration) Helicoll: Helicoll Collagen I Wound Dressing
Overall Study
Adverse Event
1
Overall Study
Lost to Follow-up
1
Overall Study
Withdrawal by Subject
1
Overall Study
inconsistent dressing application
1

Baseline Characteristics

Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Helicoll - Chronic Wound
n=10 Participants
Helicoll will be applied to one chronic wound (approximately 6 months or more duration) Helicoll: Helicoll Collagen I Wound Dressing
Age, Categorical
<=18 years
8 Participants
n=93 Participants
Age, Categorical
Between 18 and 65 years
2 Participants
n=93 Participants
Age, Categorical
>=65 years
0 Participants
n=93 Participants
Age, Continuous
15.6 years
STANDARD_DEVIATION 5.6 • n=93 Participants
Sex: Female, Male
Female
5 Participants
n=93 Participants
Sex: Female, Male
Male
5 Participants
n=93 Participants
Region of Enrollment
United States
10 participants
n=93 Participants

PRIMARY outcome

Timeframe: Baseline and Week 8

Change was assessed in terms of wound surface area, as measured using the ARANZ camera. Week 8 surface area measurement was compared to baseline surface area measurement and percentage in size change was calculated.

Outcome measures

Outcome measures
Measure
Helicoll - Chronic Wound
n=3 Participants
Helicoll will be applied to one chronic wound (approximately 6 months or more duration) Helicoll: Helicoll Collagen I Wound Dressing
Standard of Care Dressing - Chronic Wound
n=3 Participants
Standard of Care dressings will be applied to one chronic wound
Percentage of Wound Surface Area Change From Baseline to Week 8
-63 percentage of wound surface area
Interval -99.1 to -26.9
-8.1 percentage of wound surface area
Interval -34.4 to 18.1

Adverse Events

Helicoll - Chronic Wound

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Standard of Care - Chronic Wound

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Helicoll - Chronic Wound
n=10 participants at risk
Helicoll will be applied to one chronic wound (approximately 6 months or more duration) Helicoll: Helicoll Collagen I Wound Dressing
Standard of Care - Chronic Wound
n=7 participants at risk
Standard of Care wound dressings (e.g. Vaseline gauze) will be applied to one chronic wound (of approximately 6 months duration) if the subject has more than one chronic wound of approximately the same size and duration as Helicoll chronic wound.
Infections and infestations
wound infection
10.0%
1/10 • Number of events 1
0.00%
0/7

Additional Information

Dr. Alfred Lane

Stanford School of Medicine

Phone: 650 721 7166

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place